NeuroAI NEUROAINEUROAI.SITE
China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories
ESC

Sixty Amputees in Hong Kong Get Bionic Limbs Without Surgery

A government-funded programme pairs BrainCo's non-invasive bionic hands and legs with Hong Kong Polytechnic University, testing whether brain-computer interface technology can be delivered as a public service.

2026-11-17 · 1104 words · NeuroAI
Sixty Amputees in Hong Kong Get Bionic Limbs Without Surgery

Consider a typical user of a non-invasive bionic hand: fingers move not by implant but by electrical activity in the muscles of the residual limb, picked up by sensors in the socket.

It is a modest-looking outcome for a field better known for brain surgery. That is precisely what makes the programme worth watching.

On 26 May 2026, BrainCo (强脑科技) and The Hong Kong Polytechnic University (香港理工大学) launched a two-year scheme at the Hong Kong SAR government headquarters to fit 60 eligible amputees with smart bionic hands and legs, free of charge.

The programme, on paper

The initiative is called the BrainCo — Hong Kong Polytechnic University Smart Technology for Well-being Programme (强脑科技—香港理工大学惠民科技计划). It is funded through the Hong Kong government's Innovation and Technology Fund (创新及科技基金) and guided by the Innovation, Technology and Industry Bureau (创新科技及工业局).

The division of labour is explicit.

  • BrainCo supplies the technology — non-invasive bionic hands and legs built around its signal-processing hardware.
  • The university handles fitting, clinical evaluation and research support, testing the devices in real use and feeding user feedback back into design.
  • The first phase runs two years and covers 60 people, with both upper-limb and lower-limb devices included.
  • A joint research centre was announced at the same launch, focused on prosthetic customisation, rehabilitation systems and cross-disciplinary interaction design.

At the launch, bureau secretary Sun Dong (孙东) called it a public-welfare engineering effort, and founder Han Bicheng (韩璧丞) spoke about service and support. Those are statements of intent, not measured results.

The scheme sits under a broader policy idea — that publicly funded research should produce something residents can actually use — rather than under a medical-device approval pathway. It is a deployment programme, not a trial.

Why "non-invasive" is the whole point

BrainCo's products do not touch the brain. The bionic hand reads myoelectric (肌电) signals from the residual limb through surface sensors in the socket; the user's intended movement is decoded from muscle activity rather than from cortical neurons. After training, users can perform fine tasks such as writing or playing a musical instrument.

The bionic leg uses multiple sensors and an intelligent hydraulic system to adapt to walking intent, stairs and pace changes, with fall protection.

This places the company in a different category from implant developers.

  • There is no craniotomy, no implanted electrode and no long-term surgical risk.
  • Fitting and removal are reversible, which changes the ethics of trying a device and stopping.
  • The hard problem shifts from surgery to signal quality and training — how reliably a socket picks up intent, and how long a user needs to learn the mapping.
  • Manufacturing can look more like consumer electronics than like Class III implant production.

BrainCo was founded in 2015 in Massachusetts by Han while he was a doctoral student at Harvard, and later moved its headquarters to Hangzhou (杭州). Its Chinese operating entity is Zhejiang Qiangnao Technology Co., Ltd. (浙江强脑科技有限公司). It is one of the Hangzhou "Six Little Dragons" (杭州六小龙), a label that groups it with DeepSeek and Unitree. Its bionic hand received United States Food and Drug Administration clearance in 2022; I have not independently checked the clearance number.

According to Li An, chief scientist at BrainNet (脑机网), the most consequential brain-computer interface deployments may be the ones that never require a surgeon.

The money behind the hands

The Hong Kong programme is small — 60 people — but the company behind it is not.

On 8 January 2026, BrainCo announced a financing round of about RMB 2 billion (≈US$280 million / HK$2.2 billion), co-led by IDG Capital and Walden International (华登国际), with strategic investors including Lens Technology (蓝思科技) and OmniVision (韦尔股份). Shanghai Securities News reported that the proceeds would go toward core technology, engineering, product scaling and mass production.

Days later, on 12 January, Bloomberg reported that BrainCo had confidentially filed for a Hong Kong Stock Exchange listing. CICC (中金公司) and UBS were named as joint sponsors. As of September 2026 no hearing, pricing or listing had been reported, and the prospectus remained non-public.

The sequence is a signal: the company considers its commercial record sufficient for a public-market conversation. That is not evidence the record is profitable. The financing, investors and filing are verifiable; the valuation is not.

What a 60-person programme cannot show

This is where enthusiasm should be checked.

  • Sixty people is a feasibility cohort, not an outcomes study. I have seen no published, controlled comparison of function before and after fitting.
  • Eligibility criteria are not public in detail. The 60 places go to "eligible" amputees; without the criteria, the results cannot be generalised.
  • Success measures are soft at launch. Users describing a "good start" is not the same as a validated clinical endpoint.
  • A free programme says nothing about willingness to pay. The devices are funded by government here, which removes the question that will determine most markets.
  • Two years is short for prosthetic adoption. Abandonment rates for upper-limb prosthetics are a known problem in the field, and a launch event cannot address it.

None of this makes the programme trivial. Its value lies in follow-up data, if that data is published.

Honest limitations

The programme facts come from Chinese state and Hong Kong government sources — People's Daily's Greater Bay Area channel, Hong Kong Government News as reproduced by Sina Finance, and China Science Daily — plus Inside BCI for the corporate and financing background. I did not find an English-language government press release.

The RMB 2 billion figure is consistent across Shanghai Securities News and several industry outlets, but the exact round label was not disclosed in primary Chinese reporting, so I have called it a "round" rather than a specific series. The US dollar and Hong Kong dollar conversions are my own.

I have not verified the FDA clearance identifier because sources gave conflicting dates, and I have seen no outcome data from the 60 fittings.

What readers can do now

  • If you are an amputee in Hong Kong, ask your clinic about eligibility and the waiting list — the first phase is capped at 60 places over two years.
  • If you compare BCI companies, separate invasive and non-invasive claims. A bionic hand driven by muscle signals and an implanted cortical interface solve different problems with different risks.
  • If you are evaluating the sector, watch for published fitting-retention data. Whether people still use the device at month eighteen matters more than how many were fitted in month one.

The most interesting thing about this programme is not the technology. It is the delivery model: a non-invasive device, a university clinic and a public fund, with no operating theatre involved.

Related coverage

Cite this article

NeuroAI (脑机网), "Sixty Amputees in Hong Kong Get Bionic Limbs Without Surgery," 17 November 2026, https://neuroai.site/a/na-brain-brainco-prosthetics-hong-kong

Machine-readable: BibTeX · RIS · JSON · Markdown

More in “Brain–Computer Interface” → · Back to home · Markdown version

China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories